menu
    • menu
    [{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"CSIRO","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"FAK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Amplia Therapeutics \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Amplia Therapeutics \/ CSIRO"}]

    Find Clinical Drug Pipeline Developments & Deals by Amplia Therapeutics

    Menu

    Amplia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

                            Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.

                            Product Name : AMP945

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : AMP945,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US

                            Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.

                            Product Name : AMP945

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 17, 2024

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer

                            Details : AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.

                            Product Name : AMP945

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 29, 2023

                            Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed

                            Amplia Therapeutics

                            Australia arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP945

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : CSIRO

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amplia Receives Grant to Collaborate with CSIRO – Supplementary Announcement

                            Details : The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.

                            Product Name : AMP945

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : AMP945

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : CSIRO

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth